chemical

7189/50

7189/50

50 mg

158 USD

7189/50

Saracatinib

50 mg

Potent and selective Src tyrosine kinase family inhibitor; anticancer; antiviral; orally bioavailable

Src Family Kinase Inhibitors

Small Molecules

98%

542.03

?utm_source=labome&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

Saracatinib is a potent and selective Src tyrosine kinase family inhibitor (IC50 = 4-10 nM). Inhibits Src, c-Yes, Fyn, Lyn, Blk, Fgr, and Lck. Exhibits selectivity over other tyrosine kinases (IC50 values are 30, 66 and 200 nM for v-Abl, EGFR and c-Kit, respectively). Suppresses invasion of HT1080 cells through a collagen matrix and inhibits metastasis in a murine model of bladder cancer. Inhibits the growth of prostate cancer cell lines. Also suppresses MERS-CoV replication at the early stage of replication (EC50 = 2.9 M) and displays broad-spectrum activity against other human coronaviruses. Also blocks dengue virus RNA replication. Reverses memory deficit in a mouse AD model and rescues synapse density. Inhibits osteoclast activity, resorption and formation. Induces autophagy. Orally bioavailable.

Potent and selective Src tyrosine kinase family inhibitor; anticancer; antiviral; orally bioavailable

Potent and selective Src tyrosine kinase family inhibitor; anticancer; antiviral; orally bioavailable

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine

C27H32ClN5O5

C27H32ClN5O5

379231-04-6

158 USD

Potent and selective Src tyrosine kinase family inhibitor; anticancer; antiviral; orally bioavailable

AZD 0530

Store at -20░C